This article was originally published here<\/p>\n
Transfus Apher Sci. 2021 Jun 26:103200. doi: 10.1016\/j.transci.2021.103200. Online ahead of print.<\/p>\n
ABSTRACT<\/p>\n
Psoriasis is a chronic inflammatory skin disease that is characterized by well-demarcated erythematous plaques with a silver scale. Although many new and emerging therapeutic agents are often sufficient to control the disease, there is still a need for alternative treatment options in challenging cases. Extracorporeal photopheresis (ECP) has been applied to many T-cell-mediated diseases to restore immune homeostasis and treat psoriasis effectively. In this paper, we present a psoriasis patient who did not respond to methotrexate, narrowband ultraviolet B, or acitretin. Because of a diagnosis of non-Hodgkin lymphoma, the patient had contraindications for cyclosporine, fumaric acid esters, and biologics but achieved remission with a total of 12 sessions of ECP in two and a half months. Although exacerbation was recorded after polymerase chain reaction (PCR) confirmed coronavirus 2019 (COVID-19) disease infection at the end of the first month, scores from the psoriasis area severity index (PASI) and dermatological life quality index (DLQI) were regressed significantly within two and a half months. ECP seems to provide an effective and rapid response for psoriasis and should be considered for psoriasis patients who fail to respond or have contraindications to existing treatments.<\/p>\n
PMID:34215520 | DOI:10.1016\/j.transci.2021.103200<\/p>\n
<\/p>\n
Read this article: This article was originally published here Transfus Apher Sci. 2021 Jun 26:103200. doi: 10.1016\/j.transci.2021.103200. Continue reading
\nA case of psoriasis successfully treated by extracorporeal photopheresis during COVID-19 pandemic - DocWire News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"